Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2000 | 12-1999 | 12-1998 | 12-1997 | 12-1996 | |
| Sales | 10,862,200 | 10,002,900 | 9,236,800 | 8,517,600 | 7,346,600 |
| Cost of Goods | 2,055,700 | 2,098,000 | 2,015,100 | 2,362,900 | 2,118,400 |
| Gross Profit | 8,806,500 | 7,904,900 | 7,221,700 | 6,154,700 | 5,228,200 |
| Operating Expenses | 5,247,500 | 4,541,200 | 4,397,300 | 3,697,300 | 3,181,800 |
| Operating Income | 3,559,700 | 3,363,700 | 2,824,500 | 2,458,300 | 2,046,800 |
| Interest Expense | 182,300 | 183,800 | 181,300 | 234,100 | 288,800 |
| Other Income | 481,300 | 65,500 | 21,800 | -1,714,000 | 273,300 |
| Pre-tax Income | 3,858,700 | 3,245,400 | 2,665,000 | 510,200 | 2,031,300 |
| Income Tax | 800,900 | 698,700 | 568,700 | 895,300 | 507,800 |
| Net Income Continuous | 3,057,800 | 2,517,000 | 2,096,300 | 2,015,900 | 1,457,924 |
| Net Income Discontinuous | N/A | 174,300 | 1,600 | 0 | 0 |
| Net Income | $3,057,800 | $2,721,000 | $2,097,900 | $-385,100 | $1,523,500 |
| EPS Basic Total Ops | 2.83 | 2.50 | 1.91 | -0.35 | 1.39 |
| EPS Basic Continuous Ops | 2.83 | 2.31 | 1.91 | 1.83 | 1.33 |
| EPS Basic Discontinuous Ops | N/A | 0.16 | 0.00 | N/A | N/A |
| EPS Diluted Total Ops | 2.79 | 2.46 | 1.87 | -0.34 | 1.39 |
| EPS Diluted Continuous Ops | 2.79 | 2.28 | 1.91 | 1.78 | 1.33 |
| EPS Diluted Discontinuous Ops | N/A | 0.16 | 0.00 | N/A | N/A |
| EBITDA(a) | $3,995,500 | $3,803,400 | $3,314,900 | $2,968,100 | $2,590,300 |